Dr. Reddy's Laboratories (NYSE:RDY) and its subsidiary, Promius Pharma™, LLC today announced the filing of three 505(b)(2) New Drug Applications (NDAs) with the U.S. Food and Drug Administration (US FDA).
Promius Pharma, LLC has announced that ZENATANE™(Isotretinoin Capsules USP) are now available in a 30mg dose. Zenatane, AB rated equivalent to Accutane 30mg, has been introduced in response to dermatologists who have continued to request this strength of the drug.
Promius Pharma, LLC, has acquired the rights to market and distribute Trianex® 0.05% (Triamcinolone Acetonide Ointment, USP) in the United States from CMP Pharma, Inc.
Promius Pharma and Valeant form collaboration to market Cloderm® Cream in the United States.
Promius Pharma, LLC has announced the launch of Promiseb™ Topical Cream, a non-steroidal, prescription only, cream for the treatment of seborrheic dermatitis, that has demonstrated both anti-inflammatory and antifungal properties.
Promius Pharma, LLC, has launched Scytera™(coal tar) Foam 2% for the treatment of chronic psoriasis, a skin disease that affects approximately 7.5 million Americans according to The National Psoriasis Foundation.
September 18, 2008
Dr. Reddy's formally announces its US Specialty Business, Promius Pharma, LLC
September 03, 2008
Antares Pharma enters into a feasibility development agreement with Dr. Reddy's Laboratories for an enhanced dermatology product utilizing the ATD gel platform.
September 27, 2007
Sinclair Pharma plc announces Dr Reddy's Laboratories as Sebclair marketing partner in US.
January 24, 2007
Foamix signs R&D collaboration and license agreement with Dr. Reddy's for the development and commercialization of psoriasis foam.